Want to see BCAX full AI Analyst Report?
Top Page
Bicara Therapeutics Inc.
(NASDAQ:BCAX)
Select Model
Select Model
Rating:56Neutral
Price Target:
$18.50
▼(-25.19% Downside)
Action:Reiterated
Date:08/26/26
The score is anchored by weak financial performance typical of a pre-revenue biotech (widening losses and heavy negative free cash flow), partially mitigated by a strong low-debt balance sheet and reported cash runway. Earnings-call updates add meaningful upside from clinical progress and funded milestones, but near-term technical momentum is weak and valuation metrics offer limited support due to ongoing losses and no dividend.
Positive Factors
Durable clinical efficacy
The reported three-year survival signal and durable responses provide meaningful clinical validation for Ficera in a serious oncology setting. If confirmed in the pivotal study, this durability could support differentiation, physician adoption, and a stronger foundation for future regulatory and commercial execution.
Negative Factors
No commercial revenue
The absence of product revenue means Bicara has not yet demonstrated a commercial earnings engine and remains dependent on clinical success and regulatory approval. Until a candidate is approved and launched, operating progress will not be supported by recurring customer-funded revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Durable clinical efficacy
The reported three-year survival signal and durable responses provide meaningful clinical validation for Ficera in a serious oncology setting. If confirmed in the pivotal study, this durability could support differentiation, physician adoption, and a stronger foundation for future regulatory and commercial execution.
Read all positive factors
Bicara Therapeutics Inc. (BCAX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.23B
Dividend YieldN/A
Average Volume (3M)571.48K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue GrowthN/A
EPS Growth-63.70%
CountryUS
Employees103
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.10
Shares Outstanding66,172,935
10 Day Avg. Volume752,859
30 Day Avg. Volume571,481
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.29
Price to Sales (P/S)0.00
P/FCF Ratio-8.59
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.89Price Target Upside32.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.41
Revenue Forecast (FY)N/A
Bicara Therapeutics Inc. Business Overview & Revenue Model
Company Description
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tum...
How the Company Makes Money
As a clinical-stage biotechnology company, Bicara Therapeutics’ primary economic activity is advancing drug candidates through discovery, preclinical development, and clinical trials rather than generating recurring revenue from product sales. Det...
Bicara Therapeutics Inc. Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical and operational momentum: mature 3-year efficacy and safety data for Ficera (≈33% 3-year survival, ~2x SOC), clear milestones (interim OS analysis mid-2027), initiation of an alternative dosing study timed for potential approval, and a planned leadership succession to support commercialization. These positives are balanced against rising operating expenses and planned commercialization spend, competitive timing uncertainty from other EGFR-directed agents, and small early CRC cohorts that will require further validation. Overall, the highlights—particularly the robust long-term efficacy signal, funded runway into H1 2029, and deliberate commercialization preparations—outweigh the near-term execution and competitive risks.Positive Updates
Pivotal Phase III (FORTIFI-HN01) Progress
FORTIFI-HN01 is on track for substantial enrollment by year-end with over 200 sites now active and sustained investigator engagement; company positioned for a top-line interim overall survival analysis in mid-2027.
Negative Updates
Rising Operating Expenses
Total operating expenses for Q2 2026 increased versus Q2 2025 driven by clinical operations, development and manufacturing costs and higher personnel-related expenses (including stock-based compensation); management expects quarter-over-quarter operating expenses to increase for the remainder of the year.
Read all updates
Q2-2026 Updates
Positive
Negative
Pivotal Phase III (FORTIFI-HN01) Progress
FORTIFI-HN01 is on track for substantial enrollment by year-end with over 200 sites now active and sustained investigator engagement; company positioned for a top-line interim overall survival analysis in mid-2027.
Read all positive updates
Company Guidance
Management guided that Bicara expects to be substantially enrolled in the pivotal Phase III FORTIFI‑HN01 by year‑end 2026 (>200 active sites, ~20% U.S. sites; pivotal dose 1,500 mg weekly), positioning the company for a top‑line interim analysis in mid‑2027; they have initiated the FORTIFI‑FLEX alternative dosing study (≈1/3 site overlap with FORTIFI) to support a loading + every‑3‑week maintenance regimen with data aimed to be in hand by potential U.S. approval. Financially, Bicara ended Q2 2026 with ≈$497M in cash, cash equivalents and marketable securities, which management said provides runway into H1 2029 to fund the pivotal OS analysis, a planned regulatory filing, initial commercial/medical investments, FORTIFI‑FLEX and manufacturing; they also cautioned that operating expenses have increased year‑over‑year and are expected to rise quarter‑over‑quarter through year‑end as clinical, technical and commercial readiness investments continue. They reiterated clinical progress from Phase Ib (~90 patients across 3 dose cohorts, up to 3 years follow‑up), noting at the 1,500 mg weekly dose an estimated ~1 in 3 patients alive at 3 years (~33%, nearly 2× OS versus retrospective pembrolizumab).Bicara Therapeutics Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
76
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -184.38M | -137.63M | -67.75M | -51.96M | -37.72M |
| Net Income | -185.36M | -137.95M | -68.00M | -51.98M | -37.84M |
Balance Sheet | |||||
| Total Assets | 512.24M | 430.99M | 569.20M | 233.98M | 6.70M |
| Cash, Cash Equivalents and Short-Term Investments | 497.26M | 414.80M | 489.71M | 230.44M | 4.16M |
| Total Debt | 1.16M | 1.71M | 738.00K | 657.00K | 0.00 |
| Total Liabilities | 43.48M | 29.54M | 77.32M | 15.47M | 23.98M |
| Stockholders Equity | 468.77M | 401.45M | 491.88M | 218.51M | -17.28M |
Cash Flow | |||||
| Free Cash Flow | -135.25M | -107.11M | -74.82M | -46.21M | -32.27M |
| Operating Cash Flow | -134.85M | -106.83M | -74.75M | -45.63M | -32.08M |
| Investing Cash Flow | -402.50M | -318.45M | -9.00K | -586.00K | -192.00K |
| Financing Cash Flow | 197.34M | 32.26M | 334.03M | 272.50M | 31.70M |
Bicara Therapeutics Inc. Technical Analysis
Negative
24.73
Price Trends
23.85
Negative
23.99
Negative
21.32
Negative
Market Momentum
-1.54
Positive
25.69
Positive
2.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCAX, the sentiment is Negative. The current price of 24.73 is above the 20-day moving average (MA) of 21.56, above the 50-day MA of 23.85, and above the 200-day MA of 21.32, indicating a bearish trend. The MACD of -1.54 indicates Positive momentum. The RSI at 25.69 is Positive, neither overbought nor oversold. The STOCH value of 2.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCAX.
Bicara Therapeutics Inc. Risk Analysis
Bicara Therapeutics Inc. disclosed 83 risk factors in its most recent earnings report. Bicara Therapeutics Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bicara Therapeutics Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.59B | -11.34 | -56.19% | ― | -32.27% | -21.09% | |
56 Neutral | $1.23B | -5.88 | -41.49% | ― | ― | -63.70% | |
56 Neutral | $1.69B | -3.65 | -57.79% | ― | 12.58% | 28.42% | |
56 Neutral | $1.68B | -7.82 | -59.36% | ― | -86.20% | -476.63% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | $1.92B | -12.44 | -9.96% | ― | -20.44% | -349.84% | |
47 Neutral | $729.08M | -3.52 | -50.12% | ― | -30.42% | -23.31% |
* General Sector Average
BCAX
Bicara Therapeutics Inc.
18.20
1.49
8.92%
SRPT
Sarepta Therapeutics
17.57
-4.78
-21.39%
WVE
Wave Life Sciences
3.88
-3.14
-44.73%
NTLA
Intellia Therapeutics
12.12
-8.32
-40.70%
STOK
Stoke Therapeutics
26.01
1.19
4.79%
TSHA
Taysha Gene Therapies
4.74
-0.14
-2.87%
Bicara Therapeutics Inc. Corporate Events
Business Operations and Strategy
Bicara Therapeutics Secures Boston Headquarters Through Sublease
Positive
Aug 25, 2026
On August 21, 2026, Bicara Therapeutics Inc. entered into a sub-sublease agreement with Wayfair LLC to secure approximately 35,090 square feet of office space at 10 St. James Avenue in Boston for its new corporate headquarters. The lease term will...
Business Operations and StrategyExecutive/Board Changes
Bicara Therapeutics reshapes board for commercialization push
Positive
Jul 28, 2026
On July 28, 2026, Bicara Therapeutics announced the appointments of industry veterans Jeremy Bender and Christy Oliger to its board of directors, adding deep strategic, commercial and operational expertise as the company transitions from a clinica...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.